SWA
TVRD

SFMG Wealth Advisors’s Tvardi Therapeutics TVRD Stock Holding History

SFMG Wealth Advisors’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-242
Closed -$200K – 163
2019
Q2 		$200K Buy
+242
New +$170K 0.03% 147

Other funds holding TVRD

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

SFMG Wealth Advisors's TVRD Position: Q3 2019 in Review

SFMG Wealth Advisors sold out of Tvardi Therapeutics (TVRD) in Q3 2019, closing a stake of 242 shares — an estimated $200K sold.

SFMG Wealth Advisors first reported a position in TVRD in Q2 2019 and held it in 1 quarter. The position peaked at $200K in Q2 2019. 144 funds tracked by Wall St. Rank hold TVRD as of Q3 2019.

  • SFMG Wealth Advisors reported no remaining Tvardi Therapeutics position as of Q3 2019 after selling out during the quarter.
  • SFMG Wealth Advisors sold 242 Tvardi Therapeutics shares in Q3 2019, an estimated $200K.
  • SFMG Wealth Advisors first reported a position in Tvardi Therapeutics in Q2 2019 and held it in 1 quarter.
  • SFMG Wealth Advisors's Tvardi Therapeutics position peaked at $200K in Q2 2019.
  • 144 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2019.

Based on SFMG Wealth Advisors's 13F filing for Q3 2019, filed 29 Oct 2019.